Benchmark Maintains Buy on Humacyte, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has maintained a Buy rating on Humacyte (NASDAQ:HUMA) but has reduced the price target from $16 to $15.

December 27, 2023 | 7:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Benchmark analyst Bruce Jackson maintains a Buy rating on Humacyte but lowers the price target from $16 to $15.
The reduction in price target by Benchmark could have a mixed impact on Humacyte's stock price. While the Buy rating reaffirms a positive outlook, the lowered price target may signal a tempered expectation for the stock's growth potential. Investors may perceive the price target cut as a negative signal, potentially leading to short-term price volatility. However, the continued Buy rating suggests that the overall sentiment remains positive, which could mitigate any negative reaction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100